SpheroTest validated by Clinical Research

First the biological similarity of the microtumors used in the SpheroTest was verified in basic research. Then the good results of SpheroTest have been observed in approximately 500 cases for various tumor entities. Finally the clinical benefit of the SpheroTest has been systematically analysed at various leading clinics in clinical trials. The SpheroNEO study was published in BMC Cancer 2015. In neoadjuvant breast cancer, it documented a prediction force of over 95% and a doubling of the rate to be tumor free (PCR rate) to more than 52%). The results of the studies in the field of ovarian cancer (ovarian) and gastrointestinal cancer will be available in 2017.

Contact

Call our experts for a free consultation: +49 89 540 41 34-0


Our lab and company
Our research services

spherotec - spheroids for anti-cancer drug selection